Limited neural input results in muscle weakness in neuromuscular disease because of a reduction in the density of muscle innervation, the rate of neuromuscular junction activation or the efficiency of synaptic transmission 1 . We developed a small-molecule fast-skeletal-troponin activator, CK-2017357, as a means to increase muscle strength by amplifying the response of muscle when neural input is otherwise diminished secondary to neuromuscular disease. Binding selectively to the fast-skeletal-troponin complex, CK-2017357 slows the rate of calcium release from troponin C and sensitizes muscle to calcium. As a consequence, the force-calcium relationship of muscle fibers shifts leftwards, as does the force-frequency relationship of a nerve-muscle pair, so that CK-2017357 increases the production of muscle force in situ at sub-maximal nerve stimulation rates. Notably, we show that sensitization of the fast-skeletaltroponin complex to calcium improves muscle force and grip strength immediately after administration of single doses of CK-2017357 in a model of the neuromuscular disease myasthenia gravis. Troponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised.
Skeletal muscle contraction occurs after motor neuron firing and the transmission of this impulse across the neuromuscular junction. The ensuing muscle action potential triggers the release of calcium from the sarcoplasmic reticulum. As the frequency of nerve firing increases, the amount of calcium released from the sarcoplasmic reticulum also increases, causing the force of muscle contraction to ramp up proportionally from a twitch to a maximal tetanic contraction 2 . The relationship of the frequency of motor neuron firing to the corresponding muscle force is termed rate coding 3 and is one of the means by which muscle strength is controlled. Under normal conditions, skeletal muscle operates in a range of forces between 10% and 65% of its maximum tetanic force 4 .
In many diseases, muscle weakness is the result of limited neural input and can lead to substantial disability and increased mortality. Peripheral motor neuropathies such as amyotrophic lateral sclerosis, spinal muscular atrophy and Charcot-Marie-Tooth disease cause motor neuron damage and death, which strains the ability of the surviving motor neurons to stimulate muscle effectively to generate force [5] [6] [7] [8] . In myasthenia gravis, weakness and fatigue result from the failure of signal transmission at the neuromuscular junction, which limits calcium release and force production 9 ; treatment for myasthenia gravis consists of acetylcholinesterase inhibitors and immunosuppression, although weakness and fatigue are still common in affected individuals even after treatment 10 . Therapeutic options for other neuropathies are limited or nonexistent.
We hypothesized that amplifying the response of the sarcomere, the fundamental contractile unit in skeletal muscle, to inadequate motor neuron input would improve muscle force generation and physical function in individuals with neuromuscular diseases. One way to amplify the sarcomere response is to increase the calcium sensitivity of the troponin-tropomyosin regulatory complex, which is the calcium sensor within the sarcomere that regulates the actin-myosin force-generating interaction. We identified a structural class of fastskeletal-troponin activators using high-throughput screens of fast (type 2) and slow (type 1) skeletal myofibrils. We then optimized this compound class for potency, physiochemical properties and pharmacokinetics, leading to the synthesis of CK-2017357 (molecular weight, 230.3; Fig. 1a) .
CK-2017357 selectively sensitizes fast skeletal muscle to calcium by binding to its troponin complex. We prepared nearly pure populations of fast, slow and cardiac myofibrils from the following well characterized sources [11] [12] [13] [14] : rabbit psoas (fast), bovine masseter (slow) and bovine cardiac muscle (we confirmed the muscle composition using myosin-heavy-chain analyses; Supplementary Fig. 1a ). The addition of CK-2017357 to fast skeletal myofibrils resulted in a leftward shift of the myosin ATPase relationship to calcium concentration (pCa is the negative logarithm of the free calcium concentration) (Fig. 1b) , with the pCa producing a half-maximal increase in ATPase (pCa 50 ) shifting from 5.61 ± 0.01 (mean ± s.e.) before treatment (control) to 6.52 ± 0.02 after the addition of 5.0 µM CK-2017357. We characterized the potency of CK-2017357 by measuring the effect of increasing compound concentration on the myosin ATPase rate at a fixed calcium concentration (pCa = 6.0), resulting in a half maximal effective concentration (EC 50 ) for CK-2017357 treatment of 390 ± 17 nM (mean ± s.e.) (Fig. 1c) . CK-2017357 had little or no effect in myofibrils from slow skeletal and cardiac muscle (Fig. 1c) , showing its selectivity for fast skeletal muscle. Activation of myofibrils from bovine rectus abdominis muscle (EC 50 = 770 ± 100 nM; Supplementary Fig. 1b ), a muscle with mixed fiber types that contains, in part, fast skeletal muscle, confirmed its selectivity profile in muscle derived from the same species.
We leveraged this selectivity to determine the target of CK-2017357 using heterologous reconstituted versions of troponin-tropomyosinregulated actin-myosin 15 . CK-2017357 activated only those reconstitutions containing the fast-skeletal-troponin complex (Fig. 1d) . Isothermal titration calorimetry further confirmed a direct interaction of CK-2017357 with fast skeletal troponin (K d = 40 ± 6 nM (mean ± s.d.)). Addition of CK-2017357 to a purified fast-skeletaltroponin complex resulted in an exothermic reaction that fit well with a single-site-binding model. Consistent with its myofibril selectivity, CK-2017357 had a modest affinity for slow skeletal troponin (K d = 3,800 ± 700 nM) and no measureable affinity for cardiac troponin (Fig. 2a) . This selectivity is not surprising, given the substantially different amino acid composition (~50%) of each corresponding troponin subunit isoform in slow skeletal and cardiac muscle.
The troponin complex contains three subunits, troponin C, troponin I and troponin T. Troponin C is a calcium sensor with four binding sites, two of which have high affinity (K d ~50 nM) and two of which have low affinity (K d ~2 µM) 16 . After calcium release from the sarcoplasmic reticulum, binding to the low-affinity sites results in tropomyosin movement and allows the actin-myosin interaction to proceed 17 . As calcium is pumped back into the sarcoplasmic reticulum, calcium concentrations fall, the low-affinity sites release calcium and the muscle contraction ends. We measured calcium release from the low-affinity sites of fast skeletal troponin using a fluorescent calcium indicator in a stopped-flow apparatus. Addition of CK-2017357 (20 µM) slowed the first order rate constant for Ca 2+ release from 14.7 s −1 (95% CI 14.5-14.8) to 4.0 s −1 (95% CI 3.9-4.1), which is consistent with CK-2017357 increasing the affinity of troponin for calcium (Fig. 2b) . Similar experiments with isolated fast skeletal troponin C did not show either a change in the calcium release rate (Fig. 2c) or a binding interaction (Fig. 2d) , suggesting that the CK-2017357 binding site lies at an interface between two or more troponin subunits.
We sought to understand how an increase in troponin calcium affinity would translate into changes in muscle force. We prepared chemically 'skinned' human muscle fibers with the plasma membranes rendered freely permeable to Ca 2+ from muscle biopsies of the vastus lateralis, which is a mixed fast (type 2a, 2x myosins) and slow (type 1 myosin) muscle. These fibers contract when exogenous calcium is added to the muscle fiber. npg leftwards without increasing the maximum recorded force or the shape of the curve; in contrast, slow fibers were approximately tenfold less responsive to CK-2017357 than the fast fibers (Fig. 3a) . Skinned skeletal muscle fibers from rabbit (fast fibers) and rat (slow fibers) showed similar fiber-type selectivity to the human skeletal muscle fibers and, notably, skinned cardiac muscle fibers obtained from rat heart were unresponsive to CK-2017357 (60 µM) (Fig. 3b) . These experiments confirmed the selectivity of CK-2107357 for fast skeletal muscle in an intact muscle system. Given its effects on calcium sensitivity, the addition of CK-2017357 should result in an increase in the response of muscle to nerve stimulation. To test this hypothesis, we measured the response of living skeletal muscle to treatment with CK-2017357 using an in situ preparation of the extensor digitorum longus (EDL) muscle in rat, where the nerve and the blood supply are intact 18 . In this fast fiber skeletal muscle, systemic infusion of CK-2017357 resulted in rapid, dose-dependent increases in muscle force (Supplementary Fig. 2) . Examination of the force-frequency relationship in this muscle revealed a substantial increase in muscle force at sub-maximal stimulation rates as a result of treatment without increasing the maximum tension at the maximal tetanic stimulation rates (Fig. 3c) . Tension in the absence of nerve stimulation did not change after treatment (data not shown). Thus, the change in the force-frequency relationship seen here as a result of treatment was consistent with the effect of CK-2017357 on the force-calcium relationship in human and rabbit fast skinned muscle fibers.
The leftward shift of the force-frequency relationship of rat fast skeletal muscle in situ led us to test whether CK-2017357 could increase muscle force in a model of neuromuscular disease. Passive transfer experimental autoimmune myasthenia gravis npg (PT-EAMG) is a rat model of myasthenia gravis in which treatment with an inhibitory monoclonal antibody that binds to the α1, α3 and α5 isoforms of the nicotinic acetylcholine receptor (nAChR) leads to muscle weakness and fatigue 19 . Injection with this antibody (anti-nAchRα antibody) led to a substantial decline in grip strength (~50%) in PT-EAMG rats, reaching a plateau at 72 h (Fig. 4a) that remained stable at 96 h after administration. Underlying this weakness in grip strength was a decrease in muscle force caused by anti-nAchRα antibody treatment when measured in situ across a wide range of nerve-stimulation frequencies (Fig. 4b) . In an in situ preparation of the EDL in these PT-EAMG rats 72 to 96 h after antinAchRα antibody treatment, administration of CK-2017357 rapidly increased muscle force (Fig. 4c) and eliminated the decline in force produced by prolonged stimulation, the so-called use-dependent fatigue or sag (Fig. 4d,e) .
We next tested whether these increases in the performance of individual, intact muscles could translate to enhanced physical performance in the same PT-EAMG model. After randomization of the PT-EAMG rats into two groups, we orally dosed the rats with either CK-2017357 or vehicle in a blinded fashion at 72 h after injection of anti-nAchRα antibody, which we followed with a cross-over to the opposite treatment at 96 h after injection. We performed grip-strength assessments 60 min after CK-2017357 administration. CK-2017357 treatment increased the grip strength of treated rats by up to 0.97 kg per kg of body weight relative to the increase seen in rats treated with vehicle 60 min after dosing, representing a more than 50% increase in grip strength in the treated rats relative to baseline (Fig. 4f) . Of note, control rats (saline injection instead of anti-nAchRα antibody injection) randomized to CK-2017357 or vehicle treatment 72 h after their injection did not show a change in grip strength 60 min after treatment with CK-2017357 compared to baseline and to the vehicle-treated group (Fig. 4g) , suggesting that the increases in muscle function caused by CK-2017357 in this setting required prior weakness produced by neuromuscular blockade.
CK-2017357 is a selective sensitizer of the fast-skeletal-troponin complex and a direct activator of skeletal muscle function. CK-2017357 may be a therapeutic option for a range of serious neuromuscular disorders by increasing muscle strength and reducing fatigability. Evidence also points to a reduced efficiency of motorneuron excitation-contraction coupling in the sarcopenia of old age [20] [21] [22] , suggesting a potentially broader applicability of this mechanism of action. Direct activators of the skeletal sarcomere, such as the fastskeletal-troponin activator CK-2017357, may therefore hold promise in an array of conditions marked by muscle weakness.
MeThods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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oNLINe MeThods
Materials. We used a previously described method 23 for our glycerol SDS-PAGE analysis of myosin isoforms. We prepared rabbit fast skeletal myofibrils from psoas muscle 13 , slow skeletal myofibrils from bovine masseter muscle 12 and cardiac myofibrils from bovine heart muscle 11 . Myofibrils were also prepared from bovine rectus abdominis muscle, a muscle predominantly comprised of fast fibers 12 . We purified myosin (as the S1 fragment produced by limited proteolytic treatment with chymotrypsin), actin, troponin and tropomyosin from rabbit psoas muscle for skeletal isoforms and from bovine heart for cardiac isoforms [24] [25] [26] [27] . We reconstituted versions of troponin-tropomyosinregulated actin-myosin according to published methods 28, 29 . For the in vitro skinned-fiber studies, we prepared muscle as previously described 30 . Human skeletal muscle tissue was obtained by needle biopsy from the vastus lateralis muscles of volunteer subjects after obtaining signed informed consent under a protocol reviewed and approved by the institutional review boards of the University of Michigan Medical School. The Cytokinetics Institutional Animal Care and Use Committee reviewed and approved the protocols related to the rodent models. Fluorescent reagents were purchased from Molecular Probes. Cytokinetics synthesized the CK-2017357, and the stock solutions for in vitro testing were prepared in DMSO. The final DMSO concentration in the test solutions was 1-2%.
ATPase assays. We measured the steady state ATPase activity at 25 °C using a pyruvate kinase and lactate dehydrogenase-coupled enzyme system 31 and a SpectraMax plate reader (Molecular Devices) to monitor the change in absorbance as a function of time. The buffer used was 12 mM piperazine-N,N′-bis (2-ethanesulfonic acid) (PIPES), 2 mM MgCl 2 and 1 mM dithiothreitol at pH 6.8, with 60 mM KCl being added for fast and slow skeletal myofibrils.
Isothermal titration calorimetry.
We did isothermal titration calorimetry experiments in a Micro-Cal VP-ITC MicroCalorimeter (General Electric) using 50 µM rabbit fast-skeletal-troponin complex or purified recombinant rabbit fast troponin C in PIPES buffer (12 mM K-PIPES pH 6.8, 100 mM KCl, 250 µM CaCl 2 , 5 mM β-mercaptoethanol and 3% DMSO). The reference chamber contained PIPES buffer and 3% DMSO. The ligand solution injected into the sample chamber contained CK-2017357 (300 µM). Ligand injections were made every 300 s (10 µl). To correct for the heats of dilutions of CK-2017357, we subtracted the stable heat signal from the injections near the end of the experiment from all values and used the instrument software package for data collection and analysis using a single-binding-site model.
Measurement of calcium release from troponin.
We measured the calcium release from recombinant troponin C or the troponin complex using the fluorescent calcium chelator quin-2 (ref. 32) in an SF-61DX stopped-flow fluorimeter (TgK Scientific), with excitation provided by a monochromator (337 nm, with a 10-mm slit width) and emission measured through a glass filter passing wavelengths of 495 nm or greater. Calcium standard curves prepared in the presence of the equivalent concentrations of DMSO and CK-2017357 allowed for the translation of the fluorescence intensities into calcium concentrations. The final reaction conditions were as follows: 10 µM troponin C or troponin complex (pre-incubated with equimolar supplemental CaCl 2 ), 1% DMSO (± 20 µM CK-2017357), 75 µM quin-2, 12 mM K-PIPES pH 6.8, 2 mM MgCl 2 and 1 mM dithiothreitol at 25 °C.
Muscle force measurements. We performed skinned-fiber studies as previously described 30 . After attaching human fibers with 10-0 monofilament nylon, we measured muscle force with a Model 403A force transducer and Model 322C servomotor (Aurora Scientific) at a sarcomere length of ~2.7 µm. In the human fiber studies, we distinguished fiber type based on shortening speed before measurement of isometric force 30 . Studies of rat and rabbit skinned fibers used a 400A force transducer (Aurora Scientific) and 5% methylcellulose in acetone to attach the fibers.
We measured the in situ muscle force in the EDL muscle of rats as previously described 18 using an in situ muscle apparatus (Aurora Scientific, model 806C). Administration of CK-2017357 was performed using one of two different routes depending on the experiment: intra-aortic delivery by a cannula advanced into the aorta through the contralateral femoral artery or duodenal delivery through an indwelling cannula in the duodenum (to simulate an oral dose, which was not easily administered to animals under anesthesia).
PT-EAMG.
We developed a rodent model (PT-EAMG) of myasthenia gravis based on established protocols 19 . Muscle weakness developed in this model after a single intra-peritoneal injection of 500 µg per kg of body weight of anti-nAChRα antibody (SC-58604, Santa Cruz Biotechnology), as confirmed by forelimb grip measurements (Columbus Instruments). To make the study groups more homogeneous, we randomized animals with a 40-70% drop in grip strength from baseline at 72 h after administration of the antibodies into blinded vehicle (0.5% hydroxypropyl methylcellulose and 0.2% Tween-80) and compound treatment groups (CK-2017357 at 5, 10 or 20 mg per kg of body weight). After the baseline grip assessments, rats were dosed orally with vehicle or CK-2017357, and grip strength was measured at 60 min after dosing. The efficacy of the alternative treatment was examined 96 h after antibody injection in a crossover design.
Statistical analyses.
Based on the crossover design of the grip-strength measurements in the PT-EAMG model, we performed statistical analyses of change in grip strength from baseline between active treatment and vehicle using an analysis of covariance procedure, with the rats included in the model as a random effect, baseline grip strength included as a covariate and treatment, sequence of treatment and treatment occasion (that is, the first or second treatment) included as fixed factors. Unless otherwise noted, values in the text are reported as mean ± s.e.m.
